文献速递流行病学与生物统计临床试验与 GCP

HIV感染者结核病预防治疗:系统综述与网络Meta分析

Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis.
PubMed 文献 · PLoS Med · 2021-09-14

该系统综述与网络Meta分析纳入16项随机试验,比较HIV感染者结核病预防治疗方案。结果显示含利福霉素方案在预防结核病上不劣于6-12个月异烟肼,且全因死亡和3级及以上肝毒性风险更低;较短方案完成率更高,耐药结核风险无显著差异。

要点

  • 含利福霉素方案预防结核病效果不劣于6-12个月异烟肼。
  • 6-12个月异烟肼的全因死亡和3级以上肝毒性风险更高。
  • 较短方案完成率更高,耐药结核风险无显著差异。

核心结论

  • 含利福霉素方案在预防HIV感染者结核病和死亡方面似乎更安全且至少与异烟肼方案同样有效,应视为常规照护的一部分。

研究设计与样本

  • 系统综述与网络Meta分析,检索MEDLINE、Embase和Cochrane Library至2020年6月9日。
  • 纳入20项研究(报告16项随机试验),中位样本量616例(IQR 317-1892)。
  • 8项在非洲、3项在欧洲、3项在美洲、2项在多洲设点。

主要发现

  • 6-12个月异烟肼与含利福霉素方案预防微生物学确诊结核病的疗效无差异(IRR 1.0,95%CI 0.8-1.4,p=0.8)。
  • 6-12个月异烟肼与更高的全因死亡发生率相关(IRR 1.6,95%CI 1.2-2.0,p=0.02)。
  • 6-12个月异烟肼与更高的3级及以上肝毒性风险相关(RD 8.9,95%CI 2.8-14.9,p=0.004)。
  • 较短方案相对于较长方案完成率更高。
  • 各方案间耐药结核风险无统计学显著差异。

临床怎么用

  • 含利福霉素方案应优先考虑用于HIV感染者的结核病预防治疗。
  • 选择方案时需权衡疗效、完成率和安全性,较短方案可能提高完成率。

局限性

  • 治疗后随访时间和研究地点结核发病率差异可能混淆结核病或全因死亡发生率的估计。
  • 孕妇和儿童的代表性不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tuberculosis (TB) preventive therapy (TPT) is an essential component of care for people living with HIV (PLHIV). We compared efficacy, safety, completion, and drug-resistant TB risk for currently recommended TPT regimens through a systematic review and network meta-analysis (NMA) of randomized trials. METHODS AND FINDINGS: We searched MEDLINE, Embase, and the Cochrane Library from inception through June 9, 2020 for randomized controlled trials (RCTs) comparing 2 or more TPT regimens (or placebo/no treatment) in PLHIV. Two independent reviewers evaluated eligibility, extracted data, and assessed the risk of bias. We grouped TPT strategies as follows: placebo/no treatment, 6 to 12 months of isoniazid, 24 to 72 months of isoniazid, and rifamycin-containing regimens. A frequentist NMA (using graph theory) was carried out for the outcomes of development of TB disease, all-cause mortality, and grade 3 or worse hepatotoxicity. For other outcomes, graphical descriptions or traditional pairwise meta-analyses were carried out as appropriate. The potential role of confounding variables for TB disease and all-cause mortality was assessed through stratified analyses. A total of 6,466 unique studies were screened, and 157 full texts were assessed for eligibility. Of these, 20 studies (reporting 16 randomized trials) were included. The median sample size was 616 (interquartile range [IQR], 317 to 1,892). Eight were conducted in Africa, 3 in Europe, 3 in the Americas, and 2 included sites in multiple continents. According to the NMA, 6 to 12 months of isoniazid were no more efficacious in preventing microbiologically confirmed TB than rifamycin-containing regimens (incidence rate ratio [IRR] 1.0, 95% CI 0.8 to 1.4, p = 0.8); however, 6 to 12 months of isoniazid were associated with a higher incidence of all-cause mortality (IRR 1.6, 95% CI 1.2 to 2.0, p = 0.02) and a higher risk of grade 3 or higher hepatotoxicity (risk difference [RD] 8.9, 95% CI 2.8 to 14.9, p = 0.004). Finally, shorter regimens were associated with higher completion rates relative to longer regimens, and we did not find statistically significant differences in the risk of drug-resistant TB between regimens. Study limitations include potential confounding due to differences in posttreatment follow-up time and TB incidence in the study setting on the estimates of incidence of TB or all-cause mortality, as well as an underrepresentation of pregnant women and children. CONCLUSIONS: Rifamycin-containing regimens appear safer and at least as effective as isoniazid regimens in preventing TB and death and should be considered part of routine care in PLHIV. Knowledge gaps remain as to which specific rifamycin-containing regimen provides the optimal balance of efficacy, completion, and safety.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Yanes-Lane M, Ortiz-Brizuela E, Campbell JR, et al. Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. PLoS Med. 2021. PMID: 34520459. doi:10.1371/journal.pmed.1003738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。